Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Dow
US Army
Teva
Colorcon
UBS
Moodys
Cantor Fitzgerald

Generated: May 25, 2018

DrugPatentWatch Database Preview

SUDAFED 12 HOUR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Sudafed 12 Hour, and when can generic versions of Sudafed 12 Hour launch?

Sudafed 12 Hour is a drug marketed by Glaxosmithkline and Mcneil Cons and is included in two NDAs.

The generic ingredient in SUDAFED 12 HOUR is pseudoephedrine hydrochloride. There are forty-nine drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the pseudoephedrine hydrochloride profile page.
Drug patent expirations by year for SUDAFED 12 HOUR
Synonyms for SUDAFED 12 HOUR
(+)-|x-Ae>>AE(1/4)i NIEaNI
(+)-Pseudoephedrine hydrochloride
(+)-Pseudoephedrine Hydrochloride 1.0 mg/ml in Methanol (as free base)
(+)-Pseudoephedrine hydrochloride, >=98%
(+)-Pseudoephedrine hydrochloride, Sigma Reference Standard
(1S,2S)-2-(1/4)x degrees +/->>u-1-+/-(1/2)+/-u (1/4) NIEaNI
(1S,2S)-2-(Methylamino)-1-phenyl-1-propanol Hydrochloride
(1S,2S)-2-(methylamino)-1-phenyl-propan-1-ol hydrochloride
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol hydrochloride
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol;hydrochloride
1S,2S-(+)-Pseudoephedrine hydrochloride
345-78-8
345P788
56979-55-6
6272-89-5
6V9V2RYJ8N
AC1L1TCY
Actifed Sinus Daytime
AK402032
AKOS027383893
AN-23411
API0003970
BALXUFOVQVENIU-KXNXZCPBSA-N
BB_NC-1383
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, hydrochloride (1:1), (alphaS)-
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, hydrochloride, (alphaS)-
Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-, hydrochloride
Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(R*,R*))-
Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(R*,R*))- (9CI)
Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(theta,theta))-
Benzenemethanol, hydrochloride, [S-(R*,R*)]-
Benzenemethanol, hydrochloride, S-(R,R)-
Besan
C-09673
C10H15NO.HCl
CCG-39241
CHEBI:8604
CHEMBL1200724
CoAdvil
Contac Day & Night Allergy Sinus Day Caplets
CPDD 0050
D-(alpha-(1-Methylamino)ethyl)benzyl alcohol hydrochloride
D-[.alpha.-(1-Methylamino)ethyl]benzyl alcohol hydrochloride
d-I+/-Ae>>AE(1/4)i NIEaNI
d-OiAe>>AE(1/4)i NIEaNI
d-Pseudoephedrine hydrochloride
D00485
Deconsal II
Dimetapp Decongestant
Dorcol
EC 206-462-1
Efidac 24 Pseudoephedrine Hcl
EINECS 206-462-1
First sign
Histalet Syrup
HMS1920N04
Isoephedrine Hydrochloride
L-(+)-Pseudoephedrine hydrochloride
L(+)-Pseudoephedrine hydrochloride
LS-125924
MLS001304069
Nexafed
Novafed
NSC 106567
NSC 33634
NSC-106567
NSC-33634
NSC-759616
NSC106567
NSC33634
NSC759616
Ornex and Maximum Strength Ornex
Otrinol
P1654
PediaCare Decongestant Drops
Pharmakon1600-01500516
Pseudoephedrine Hcl
PSEUDOEPHEDRINE HYDROCHLORIDE
Pseudoephedrine hydrochloride (USP)
Pseudoephedrine hydrochloride [USAN:USP]
Pseudoephedrine hydrochloride [USAN]
Pseudoephedrine hydrochloride, British Pharmacopoeia (BP) Reference Standard
Pseudoephedrine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Pseudoephedrine hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Pseudoephedrine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Pseudoephedrine, (+)-
Pseudoephedrine, hydrochloride, L-(+)-
Pseudoephedrine, L-(+)-
Pseudophedrine hydrochloride
psi-Ephedrine Hydrochloride
Rhinalair
SCHEMBL33285
Sine-Aid, Maximum Strength
Sine-Off Maximum Strength No Drowsiness Formula Caplets
Sinufed
SMR000718787
SPECTRUM1500516
Sudafed (TN)
Sudafed 24 Hour
Sudafed hydrochloride
Sudafed Liquid, Children's
Sudomyl
Sun mark sinus
Suphedrine
Symptom 2
Topcare 12 hour decongestant
Tussaphed
Tylenol Sinus Medication, Maximum Strength
UNII-6V9V2RYJ8N
W-106727
WLN: QYR & Y1 & M1 & GH-L

US Patents and Regulatory Information for SUDAFED 12 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SUDAFED 12 HOUR pseudoephedrine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 017941-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mcneil Cons SUDAFED 12 HOUR pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 073585-001 Oct 31, 1991 OTC No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Federal Trade Commission
Baxter
AstraZeneca
Julphar
Deloitte
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.